Rapid Detection of TB from Blood using Cell-Free DNA and CRISPR

使用无细胞 DNA 和 CRISPR 快速检测血液中的结核病

• 批准号: 10620065
• 负责人: Richard S Garfein
• 金额: $ 79.52万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-17 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10620065
• 关键词: Address; Adult; Affinity; Aftercare; Arkansas; Binding; Biological Assay; Biological Markers; Blood; Blood Tests; Blood specimen; COVID-19; California; Cessation of life; Child; Childhood; Clinical; Clinical Research; Clinical Sensitivity; Clustered Regularly Interspaced Short Palindromic Repeats; Collaborations; Communicable Diseases; Cryopreservation; DNA; DNA Binding; Detection; Diagnosis; Diagnostic; Diagnostic Sensitivity; Diagnostic Specificity; Disease; Drug resistance in tuberculosis; Extinction; Fluorescence; Goals; Growth; HIV; Immunocompromised Host; Laboratories; Lateral; Lung diseases; Mexico; Microscopy; Molecular; Monitor; Mycobacterium tuberculosis; Nonlinear Dynamics; Pakistan; Paper; Patient-Focused Outcomes; Patients; Pediatrics; Performance; Persons; Pharmaceutical Preparations; Pilot Projects; Predisposition; Process; Proteins; Reader; Reference Standards; Reporter; Reporting; Research; Resource-limited setting; Risk; Sampling; Sensitivity and Specificity; Signal Transduction; South Africa; Specificity; Sputum; Testing; Triage; Tuberculosis; Tuberculosis diagnosis; United States National Institutes of Health; Universities; accurate diagnosis; biobank; cell free DNA; co-infection; cohort; cost; cross reactivity; detection assay; detection limit; diagnostic criteria; innovation; isothermal amplification; lateral flow assay; molecular diagnostics; mortality; non-tuberculosis mycobacteria; novel; nuclease; peripheral blood; point-of-care diagnostics; prospective; rapid detection; rapid diagnosis; rapid test; technology platform; transmission process; tuberculosis diagnostics; tuberculosis treatment

Project Summary While >90% of TB cases are curable, treatment is dependent on diagnostics based exclusively on the detection of Mycobacterium tuberculosis (Mtb) in patient sputum, despite the limitations of sputum as a diagnostic sample. Sputum is difficult to process, almost impossible to obtain from patients with paucibacillary TB, such as people living with HIV (PLWH) and children and is not diagnostic for patients with extrapulmonary TB. A low- cost, rapid test using blood instead of sputum could transform TB diagnosis for ALL patients and reduce the current diagnostic gap between patients with and without HIV co-infection. Most active TB disease (ATB) is still diagnosed with sputum smear microscopy, despite its low sensitivity and specificity. This lack of diagnostic rigor contributes to the ongoing underdiagnosis of ~3 million TB cases/year, resulting in continued transmission and poor patient outcomes, especially among PLWH in whom mortality is highest. Our long-term goal is to transform TB diagnosis with a blood test that accurately distinguishes patients with ATB from latent TB infection (LTBI), and other pulmonary disorders regardless of co-infection with HIV. The objective of this study is to demonstrate the analytical and clinical performance of a novel assay for rapid diagnosis and treatment monitoring of ATB that exploits the precise molecular affinity of CRISPR and promiscuous nuclease activity of Cas12a to detect ultra-low concentrations of Mtb cell free DNA (cfDNA) circulating in blood. Preliminary analytical studies indicate assay detection limits of <1fg/µL of Mtb cfDNA in blood and no cross-reactivity with non-tuberculosis mycobacteria (NTM) DNA. Preliminary clinical studies including adults and children with presumptive TB, as well as samples from a diagnostically challenging cohort of symptomatic immunocompromised children living with HIV, demonstrated high diagnostic sensitivity and specificity in a pooled adult and pediatric group (>90%), and high diagnostic sensitivity (85%) in children. We will achieve our proposed objective through the following specific aims: AIM 1: Validate a lateral flow version of the CRISPR-TB assay for low resource settings. Our current working assay requires a PCR step and fluorescence reader. Preliminary studies indicate we can significantly simplify this workflow using isothermal amplification and a novel lateral flow (LF) strip for detection of Mtb cfDNA. We will expand on our pilot studies to validate the existing LF assay using contrived and clinical samples. AIM 2: Define the dynamics of the Mtb cfDNA signal for treatment monitoring. Preliminary studies indicate the Mtb cfDNA signal decreases to extinction after treatment initiation but can have non-linear dynamics. We will define the variability and trajectory of the Mtb cfDNA signal in biobanked serial samples from 34 patients treated for drug resistant TB over a year, and 50 prospectively collected patients with drug susceptible TB treated over six months. AIM 3: Determine the clinical sensitivity and specificity of the CRISPR-TB assay in field settings. We will prospectively collect and test blood samples from 450 patients at risk for TB in TB-endemic field settings with high (South Africa), medium (Pakistan) and low (Mexico) HIV burden.

项目总结